Literature DB >> 9422316

Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.

K J Busam1, K Iversen, K A Coplan, L J Old, E Stockert, Y T Chen, D McGregor, A Jungbluth.   

Abstract

The Melan-A (MART-1) gene encodes an antigen recognized by cytotoxic T cells. It has been said to be restricted in its expression to melanocytes. However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adrenocortical adenomas, 16 primary and 13 metastatic adrenocortical carcinomas, four Leydig cell tumors of the testis, and three Sertoli-Leydig cell tumors of the ovary. To evaluate the potential diagnostic role of this antibody, we studied immunoreactivity for A103 in 111 carcinomas, 40 germ cell tumors, and 33 miscellaneous nonmelanocytic epithelioid tumors. All of them were negative for A103. Our findings suggest that once melanoma is excluded, A103 can aid in the recognition of steroid hormone-producing tumors and may be particularly useful in the diagnosis of adrenocortical carcinoma. The presence of immunoreactivity for A103 practically excludes any other carcinoma that may enter into the differential diagnosis of adrenocortical tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422316     DOI: 10.1097/00000478-199801000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  27 in total

1.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

2.  Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.

Authors:  Ankur R Sangoi; Mika Fujiwara; Robert B West; Kelli D Montgomery; Joseph V Bonventre; John P Higgins; Robert V Rouse; Neriman Gokden; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Authors:  Matthias Wölfl; Katharina Merker; Henner Morbach; Stefaan W Van Gool; Matthias Eyrich; Philip D Greenberg; Paul G Schlegel
Journal:  Cancer Immunol Immunother       Date:  2010-10-24       Impact factor: 6.968

4.  Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours.

Authors:  C J Stewart; C L Nandini; J A Richmond
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

5.  Sclerosing stromal tumour in young women: clinicopathologic and immunohistochemical spectrum.

Authors:  Ecmel Isik Kaygusuz; Suna Cesur; Handan Cetiner; Hulya Yavuz; Nermin Koc
Journal:  J Clin Diagn Res       Date:  2013-08-10

6.  Immunoblot analysis of CD34 expression in histologically diverse neoplasms.

Authors:  Y Natkunam; R V Rouse; S Zhu; C Fisher; M van De Rijn
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

7.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 8.  Adrenocortical carcinosarcoma: a case report and review of the literature.

Authors:  Kotaro Sasaki; Marisa Desimone; Harsha R Rao; George J Huang; Raja R Seethala
Journal:  Diagn Pathol       Date:  2010-08-05       Impact factor: 2.644

Review 9.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

10.  Carbonic anhydrase in mouse testis and epididymis; transfer of isozyme IV to spermatozoa during passage.

Authors:  Elisabeth Ekstedt; Lena Holm; Yvonne Ridderstråle
Journal:  J Mol Histol       Date:  2004-02       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.